Japanese Government Procurement

National University Corporation - Notice of Procurement (Goods & Services)A CETUXIMAB (GENETICAL RECOMBINATION) (100MG/1VIAL) 879 VIALS B AGALSIDASE ALFA (GENETICAL RECOMBINATION) (3.5MG/1VIAL) 184 VIALS C ECULIZUMAB (GENETICAL RECOMBINATION) (300MG/1VIAL) 143 VIALS D PERTUZUMAB (GENETICAL RECOMBINATION) (420MG/14ML/1VIAL) 147 VIALS E ERIBULIN MESILATE (1MG/1VIAL) 415 ...

This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.

Japanese

Publishing date Feb 21, 2018
Type of notice Notice of Procurement (Goods & Services)
Procurement entity National University Corporation - Hokkaido
Classification
0004 Medical & Pharmaceutical Products
Summay of notice 5 Summary
(1) Official in charge ofdisbursement of the procuring
entity : Akitoshi Yoshida,President, Asahikawa Medical
University
(2) Classification of the products
to be procured : 4
(3) Nature and quantity of theproducts to be purchased :
A Cetuximab (GeneticalRecombination) (100mg/1vial) 879
vials
B Agalsidase Alfa (GeneticalRecombination) (3.5mg/1vial) 184
vials
C Eculizumab (GeneticalRecombination) (300mg/1vial) 143
vials
D Pertuzumab (GeneticalRecombination) (420mg/14mL/1vial)
147 vials
E Eribulin Mesilate (1mg/1vial)415 vials
F Rituximab (GeneticalRecombination) (500mg/mL/1vial) 305
vials
G Dexmedetomidine Hydrochloride(200μg/5vials/1case) 1,170 cases
H Alglucosidase Alfa (GeneticalRecombination) (50mg/1vial) 530
vials
I Denosumab (GeneticalRecombination) (120mg/1vial) 822
vials
J fulvestrant(250mg/2vials/1case) 255 cases
K Sugammadex Sodium(200mg/10via-ls/1case) 384 cases
L Pomalidomide(4mg/7capsules/1case) 162 cases
M Ustekinumab (GeneticalRecombination) (45mg/1vial) 186
vials
N Tocilizumab (GeneticalRecombination) (400mg/1vial) 261
vials
O Trastuzumab Emtansine(Genetical Recombination)
(100mg/1vial) 119 vials
P Pegfilgrastim (GeneticalRecombination) (3.6mg/1vial) 299
vials
Q Human fibrinogen Human thrombin
(9.5cm×4.8cm/1sheet) 411 sheets
R Micafungin Sodium(50mg/10vials/1case) 319 cases
S Lenalidomide Hydrate(5mg/40capsules/1case) 184 cases
T Palonosetron Hydrochloride(0.75mg/5vials/1case) 415 cases
U Ranibizumab (GeneticalRecombination) (10mg/mL/1vial) 351
vials
V Nivolumab (GeneticalRecombination) (20mg/1vial) 459
vials
W Nivolumab (GeneticalRecombination) (100mg/1vial) 327
vials
X Goserelin Acetate(10.8mg/1syringe) 589 syringes
Y Aflibercept (GeneticalRecombination) (40mg/mL/1vial) 763
vials
Z Paclitaxel (100mg/1vial) 707vials
AA Bortezomib (3mg/1vial) 181vials
AB Infliximab (Genetical Recombi-
nation), Remicade for I.V. Infu-
sion 100 or its equivalent orits equivalent (100mg/1vial) 3,430
vials
AC Brentuximab Vedotin (Genetical
Recombination) (50mg/1vial) 55vials
AD Pemetrexed Sodium Hydrate(100mg/1vial) 431 vials
AE Pemetrexed Sodium Hydrate(500mg/1vial) 175 vials
AF Alectinib Hydrochloride(150mg/28capsules/1case) 124 cases
AG Infliximab (Genetical Recombi-
nation), Infliximab BS for I.V.
Infusion 100mg 「NK」 or itsequivalent or its equivalent
(100mg/1vial) 798 vials
AH Landiolol Hydrochloride(150mg/5vials/1case) 275 cases
AI Abatacept (GeneticalRecombination) (250mg/1vial) 360
vials
AJ Pembrolizumab (GeneticalRecombination) (100mg/4ml/1vial)
230 vials
AK Ramucirumab (GeneticalRecombination) (100mg/10ml/1vial)
415 vials
AL Ramucirumab (GeneticalRecombination) (500mg/50ml/1vial)
158 vials
AM Golimumab (GeneticalRecombination) (50mg/0.5ml/1vial)
301 vials
AN Nusinersen Sodium(12mg/5ml/1vial) 2 vials
AO Somatropin (GeneticalRecombination) (10mg/1vial) 327
vials
AP Panitumumab (GeneticalRecombination) (400mg/20ml/1vial)
68 vials
AQ Botulinum Toxin Type A(100units/1vial) 215 vials
AR Thrombomodulin Alfa (Genetical
Recombination)(12800units/10vials/1case) 72 cases
AS Ruxolitinib Phosphate(5mg/20tab-lets/1case) 222 cases
AT Secukinumab (GeneticalRecombination) (150mg/1kit) 222
kits
AU Adalimumab (GeneticalRecombination)
(40mg/0.4ml/1syringe) 255 syringes
AV Trastuzumab (GeneticalRecombination) (60mg/1vial) 1,236
vials
AW Trastuzumab (GeneticalRecombination) (150mg/1vial) 928
vials
AX Agalsidase Beta (GeneticalRecombination) (5mg/1vial) 304
vials
AY Agalsidase Beta (GeneticalRecombination) (35mg/1vial) 31
vials
AZ Bevacizumab (GeneticalRecombination) (100mg/4mL/1vial)
748 vials
BA Bevacizumab (GeneticalRecombination) (400mg/16mL/1vial)
578 vials
BB Palivizumab (GeneticalRecombination) (50mg/1vial) 207
vials
BC Palivizumab (GeneticalRecombination) (100mg/1vial) 318
vials
(4) Delivery period : From 1 May,2018 through 31 March, 2019
(5) Delivery place : AsahikawaMedical University
(6) Qualifications forparticipating in the tendering
procedures : Suppliers eligible for
participating in the proposedtender are those who shall :
A not come under Article 4 and 5of the Regulation concerning the
Contract for Asahikawa MedicalUniversity Furthermore, minors,
Person under Conservatorship orPerson under Assistance that
obtained the consent necessary forconcluding a contract may be
applicable under cases of specialreasons within the said clause,
B have the Grade A, Grade B orGrade C qualification during fiscal
2018 in the Hokkaido area in sales
of product for participating intenders by Single qualification for
every ministry and agency,
C prove to have obtained thefirst-class license for selling
drugs in accordance with the Law on
Securing Quality, Efficacy andSafety of Products including
Pharmaceuticals and MedicalDevices,
D not be currently under asuspension of business order as
instructed by President, AsahikawaMedical University.
(7) Time limit of tender : 17 : 00
13 April, 2018
(8) Contact point for the notice :
Tetsuya Hashiba, ProcurementSection, Accounting Division,
Asahikawa Medical University,2-1-1-1 Midorigaokahigashi,
Asahikawa-shi, Hokkaido, 078-8510Japan, TEL 0166-69-3068